Table 7.

Association of LDL-C changes (from baseline to 3 months) with outcomes at 12 months

Percentage of LDL level decrease (compared with baseline)	Total	Events (n%)	HR (95% CI) unadjusted	P value	HR (95% CI) adjusted	P value
12 months
Stroke recurrence*
<30%, n (%)	3526	137 (3.9)	1.48 (0.92 to 2.39)	0.11	1.42 (0.87 to 2.30)	0.16
30%–50%, n (%)	1146	45 (3.9)	1.50 (0.88 to 2.56)	0.14	1.44 (0.84 to 2.47)	0.19
>50%, n (%)	718	19 (2.7)	Reference		Reference
MACE†
<30%, n (%)	3526	149 (4.2)	1.46 (0.92 to 2.20)	0.11	1.39 (0.88 to 2.21)	0.16
30%–50%, n (%)	1146	47 (4.1)	1.41 (0.84 to 2.36)	0.19	1.36 (0.81 to 2.28)	0.24
>50%, n (%)	718	21 (2.9)	Reference		Reference

*Patients with stroke recurrence, death and loss to follow-up within 3 months were excluded.

†Patients with MACE, death and loss to follow-up within 3 months were excluded.

LDL-C, low-density lipoprotein cholesterol; MACE, major adverse cardiovascular events.